CSIR and Laxai Sciences partners for COVID clinical trials

▴ csir-laxai-sciences-hyderabad-collaborates-covid-trials
CSIR and Laxai Sciences to seek regulatory approval for clinical trials on COVID-19 patients using combinations of antiviral and host-directed therapies

Council of Scientific & Industrial Research (CSIR), in collaboration with Laxai Life Sciences Pvt. Ltd. Hyderabad has sought regulatory approval to undertake a four-arm randomized controlled phase III clinical trial. The design principle of the study is to rationally combine and repurpose antivirals (viral-entry and replication inhibitors) and host-directed therapies (HDTs) addressing the disease-spread and pathology simultaneously and to determine safety and efficacy of the three combination drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID-19 patients.

The clinical trial named MUCOVIN, to be carried out in the partnership with Medanta Medicity, will include a total of 300 patients in four different groups of 75 patients in the trials to be carried for 17 to 21 days including screening and treatment.

Dr. Shekhar C. Mande, DG, CSIR highlighted that this unique combinatorial strategy (antivirals and HDTs) with repurposed drugs having complementary, additive and synergistic roles, has been adopted to increase therapeutic options for Covid-19 treatment and help recover patients faster. The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology, Hyderabad and CSIR-Indian Institute of Integrative Medicine, Jammu.

Dr. Ram S. Upadhayaya CEO, Laxai Life Sciences stated that “the study aims to target viral proteins essential for its replication as well as host factors that play a crucial role in the viral life cycle and contribute to the cytokine storm”. Mr. Vamsi Maddipatla, MD of Laxai Life Sciences adds “The co-sponsorship of this study by Laxai Life Sciences highlights the company’s commitment to bringing life-saving therapies in the service of humanity”.

These clinical trials add to the several contributions CSIR has made during the pandemic and if the trial is successful, it will provide more options for treatment of COVID-19.

Tags : #CSIR #Hyderabad #LaxaiSciences #HostDirectedTherapies #Mucovin #CovidClinicalTrials

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

August is Vision and Learning Month!August 08, 2020
Recovery Rate at 68% while CFR at 2.05% ; India Covid News Update Aug 8August 08, 2020
Meghalaya, Nagaland, Tripura, Mizoram COVID news update ; Aug 8 2020August 08, 2020
States, UTs to conduct Coronavirus tests of all grocery shop workers and street vendors August 08, 2020
Moderna signs up COVID Vaccine deal with Swiss government August 08, 2020
BMC makes home quarantine compulsory for domestic travellersAugust 08, 2020
Gujarat: COVID recovery rate reaches 75.04%, over 9.30 lakh tests conductedAugust 08, 2020
Serum Institute puts a ceiling of Rs 225 ,would produce 100 million doses of vaccineAugust 08, 2020
Indian Pharma on growth path, only hurdle, regulatory interventions ; PWCAugust 07, 2020
Karnataka: COVID-19 recovery rate improves to 50.73 pctAugust 07, 2020
Maharashtra: Phase-two clinical trials of Covaxin for Covid-19 to begin from Aug 10August 07, 2020
Pankajakasthuri Herbal completes successful trial of ZingiVir-HAugust 07, 2020
Obesity reduces blood flow to the brain, increasing risk to Alzheimer's diseaseAugust 07, 2020
What Is The Ideal COVID-19 Response? These 3 Countries Got It RightAugust 07, 2020
WHO sends experts to South Africa to help fight virusAugust 07, 2020
More European Nations Tighten Virus Curbs As Global COVID-19 Deaths Top 7 LakhAugust 07, 2020
UK Reimposes Quarantine For Travellers From Belgium, Bahamas Over Spike In CasesAugust 07, 2020
Govt proposes to launch National Clinical Registry for data collectionAugust 07, 2020
France, Belgium Covid-19 Cases Rising FastAugust 07, 2020
COVID-19 claims 67 additional lives in IraqAugust 07, 2020